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Abstract
Background: Obesity increases the risk for malignancies in various tissues including the stomach. Atrophic gastritis
with precancerous lesions is an obesity-associated disease; however, the mechanisms that underlie the development of
obesity-associated atrophic gastritis are unknown. Leptin is a hormone derived from stomach as well as adipose tissue
and gastric leptin is involved in the development of gastric cancer. The aim of the current study is to investigate the
involvement of leptin receptor signaling in the development of atrophic gastritis during diet-induced obesity.
Methods: Male C57BL/6, ob/ob and db/db mice were fed a high-fat diet (HFD) or a control diet (CD) from 1 week to
5 months. Pathological changes of the gastric mucosa and the expression of molecules associated with atrophic
gastritis were evaluated in these mice.
Results: HFD feeding induced gastric mucosal hyperplasia with increased gastric leptin expression. Mucosal
hyperplasia was accompanied by a higher frequency of Ki67-positive proliferating cells and atrophy of the gastric
glands in the presence of inflammation, which increased following HFD feeding. Activation of ObR signaling-
associated molecules such as ObR, STAT3, Akt, and ERK was detected in the gastric mucosa of mice fed the HFD
for 1 week. The morphological alterations associated with gastric mucosal atrophy and the expression of Muc2
and Cdx2 resemble those associated with human intestinal metaplasia. In contrast to wild-type mice, leptin-
deficient ob/ob mice and leptin receptor-mutated db/db mice did not show increased Cdx2 expression in response
to HFD feeding.
Conclusion: Together, these results suggest that activation of the leptin signaling pathway in the stomach is
required to develop obesity-associated atrophic gastritis.
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Background
Gastric carcinoma (GC) typically arises on a background
of atrophic gastritis, intestinal metaplasia, and dysplasia
of gastric mucosa, and is the second leading cause of
cancer-related deaths worldwide [1]. Obesity augments
the risk of a higher prevalence of gastritis [2, 3], atrophic
gastritis [4–6], and gastric cardia adenocarcinoma [7–9].
Infection with Helicobacter pylori, a bacterium that in-
fects humans and colonizes the stomach, is the predom-
inant cause of precancerous lesions in the mucosal
lining of the stomach [10]. Although H. pylori infection
is not confined to morbidly obese patients, obesity in-
creases the prevalence of chronic gastritis and GC [2].
Furthermore, obesity is not only a risk factor for certain
tumors but is also associated with an increased mortality
rate [11]. Thus, obesity potentially affects the develop-
ment of gastritis into gastric tumorigenesis. Therefore, it
is imperative to identify signaling molecules associated
with both obesity and precancerous lesions to aid in the
management of high-risk individuals.
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Leptin, a product of the obese (ob) gene, is primarily
produced by adipocytes and acts on its receptor (ObR) in
the hypothalamus to suppress food intake and increase
energy expenditure [12]. ObR belongs to the class I cyto-
kine receptor family, and its structure is highly homolo-
gous to that of gp130, the common signal-transducing
receptor for the interleukin-6 (IL-6) family of cytokines
[13]. Of the six alternate splice variants of ObR, only the
long isoform, ObRb, transduces a signal cascade that acti-
vates downstream Janus kinase 2 and signal transducer
and activator of transcription 3 (JAK2-STAT3), phosphoi-
nositide 3-kinase (PI3K), and extracellular signal-regulated
kinase 1/2 (ERK1/2) [14]. In addition to its role in energy
homeostasis, leptin exerts pleiotropic effects on angiogen-
esis, hematopoiesis, and immunity as well [14]. Leptin and
ObR are also expressed in various tissues including the
gastrointestinal tract [15]. Additionally, the stomach can
spontaneously express leptin and ObR, leading to the aug-
mentation of leptin receptor signaling in the stomach
during GC development [16–18]. We have previously
demonstrated the significance of leptin signaling in the
stomach and its role in the development of intestinal-type
gastric tumor using a murine model [19]. Dysfunction of
central sympathetic regulation of leptin signaling pro-
motes leptin resistance. Despite high levels of circulating
plasma leptin, obese individuals do not respond to its
appetite-suppressing effects, indicating their leptin resist-
ance [20]. Because leptin is crucial to the development of
gastrointestinal malignancies and provides a link between
obesity and tumorigenicity [17], a better understanding of
the dysregulation of gastric leptin signaling and its role in
obesity-induced gastric pathology is necessary.
Methods
Animals and diets
Male C57BL/6J (wild-type: WT), ob/ob, and db/db mice
(CLEA Japan, Tokyo, Japan) were studied at 7 weeks of
age. The animals were housed individually in plastic
cages at 24 °C ± 1 °C with lights on from 0600 to 1800 h.
The mice were provided with either a control-diet (CD,
10 % of calories from fat, D12450J) or a high-fat diet
(HFD, 60 % of calories from fat, D12492) (Research
Diets Inc., New Brunswick, NJ) and water ad libitum.
The ethics committee for animal experiments of the
National Institute for Physiological Sciences approved all
animal experiments.
Histopathological analysis of the gastric mucosa
Paraffin-embedded gastric sections of 10 % formalin-fixed
tissues were obtained from the HFD- and CD-fed mice
and were stained with hematoxylin and eosin (H&E), and
assessed for alterations in the gastric mucosa. The assess-
ment of mucosal alterations in the stomach was based on
a summation of scores for hyperplasia (0, non-substantial
alteration; 1, low; 2, moderate; 3, high), cell infiltration (0,
non-substantial alteration; 1, low; 2, moderate; 3, high),
loss of gastric glandular cells (0, non-substantial alteration;
4, low; 5, moderate; 6, high), Alcian blue staining (0, non-
substantial alteration; 4, focal; 5, diffuse; 6, very strong dif-
fuse), and dysplasia (0, non-substantial alteration; 7, low).
Each criterion was independently blind-scored by two in-
dividuals using criteria that were previously defined [19].
Intragastric pH measurements
Gastric pH was measured according to a published
method [21]. In brief, mice were sacrificed after
anesthetization by carbon dioxide inhalation. Following
stomach removal, the gastric lumen was removed and
washed with 0.5 ml saline (150 mM, pH 7.0), and the pH
of the collected gastric fluid was measured using a pH
meter (Mettler, Toledo, OH).
Immunohistochemical analysis
Paraffin-embedded sections of 10 % formalin-fixed tis-
sues were stained either with H&E or with periodic-acid
Schiff (PAS) and Alcian blue. For antigen retrieval,
deparaffinized and rehydrated specimens were treated
with 3 % hydrogen peroxide in methanol to block en-
dogenous peroxidase activity and then were heated in a
microwave using a Retrievagen A kit (BD Biosciences,
San Jose, CA), followed by overnight incubation with
primary antibodies (Abs) at 4 °C as listed in Additional
file 1: Table S1. Subsequently, the slides were stained
with a biotinylated anti-rabbit IgG or anti-goat IgG Ab
and streptavidin-labeled peroxidase using a Histofine
SAB-PO kit (Nichirei Biosciences Inc., Tokyo, Japan) and
developed using 3, 3′-diaminobenzidine (DAB) solution
(ImmPactTM DAB, Vector Laboratories, Burlingame, CA)
according to the manufacturer’s protocol, followed by
hematoxylin counterstaining. For immunofluorescence
staining, the slides were incubated with the primary Abs
(Additional file 1: Table S1) and then reacted with Alexa
488-conjugated rabbit or mouse IgG Ab or Alexa 556-
conjugated goat IgG Ab, as appropriate. The stained slides
were mounted using ProLong Gold Antifade reagent with
4′,6-diamidino-2-phenylindole (DAPI) (Life Technologies,
Carlsbad, CA) for detection using a fluorescence micro-
scope (Olympus, Tokyo, Japan).
Western blot analysis
Gastric epithelial cells were isolated and prepared ac-
cording to a modification of a previously published
method [22]. Dissected small segments of the stomach
were agitated at room temperature for 10 min in a
Hank's balanced salt solution (HBSS) (Thermo Fisher
Scientific Inc., Waltham, MA) medium containing
1 mM DTT. After removal of the supernatant, the tis-
sues were stirred at 37 °C for 10 min in HBSS containing
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10 mM EDTA. After removal of the supernatant, the tis-
sue suspension was passed through a nylon mesh to
remove debris and centrifuged through a 25/40 % discon-
tinuous Percoll (Sigma-Aldrich, St. Louis, MO) gradient at
600 × g at 20 °C for 20 min. The cells collected from the
interface of 25/40 % were the epithelial cells. Lysates were
prepared from tissues and cells and analyzed by western
blotting, according to a previously published method [23].
The Abs used in western blotting are summarized in
Additional file 1: Table S1.
Laser-capture microdissection
The above-described paraffin-embedded gastric tissues
were cut into 6-μm-thick sections and mounted onto
membrane slides (MembraneSlide 1.0 PEN, Carl Zeiss
Microscopy, LLC, Thornwood, NY). Paraffin was removed
by rinsing the sections with xylene, after which the sec-
tions were immersed in a series of 100 % to 70 % ethanol
baths and air-dried. Mucosal sections of gastric epithelia
were cut and collected onto AdhesiveCaps (PALM,
Microlaser Technologies, Bernried, Germany) by a laser-
capture microdissection (LMD) system (PALM MB-III,
Microlaser Technologies).
Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR)
Total RNA from the LMD samples and from murine
gastric mucosa was extracted using AllPrep FFPE DNA/
RNA and RNeasy Mini kits (Qiagen, Valencia, CA), re-
spectively, according to the manufacturer’s protocols.
cDNA was synthesized from approximately 100–200 ng
RNA from the LMD sections or 1–2 μg RNA from gas-
tric mucosal cells using the ReverTra Ace® qPCR RT Kit
(TOYOBO, Co., Ltd., Osaka, Japan) according to the
manufacturer’s protocol. qRT-PCR was carried out using
the Power SYBR Green PCR Master Mix (Life Technolo-
gies, Carlsbad, CA) with specific primer sets (400 nM at
the final concentration, Additional file 2: Table S2) accord-
ing to the manufacturers’ protocol. Relative changes in
gene expression were calculated using the ΔΔCt method,
and the 18S rRNA gene was used for normalization.
Quantitative analysis of immunohistochemical staining
For microscopic measurements, leptin-stained gastric mu-
cosa samples were photographed using a microscope
(Olympus), and quantitative analysis was performed using
ImageJ software (http://rsb.info.nih.gov/ij/index.html). Mu-
cosal height was measured between the base of the gastric
glands and the neck zone.
Plasma assay
Serum was collected from blood obtained by cardiocentesis
under anesthetization and stored at −80 °C. Insulin (Mouse
Insulin ELISA kit, Shibayagi, Gunma, Japan), leptin (Leptin
ELISA, Millipore, St. Charles, MO), glucose (Glucose
CII-test, Wako, Osaka, Japan), and non-esterified fatty
acid (NEFA) (NEFA C-test, Wako) levels in the sera were
measured according to the manufacturers’ protocols.
Statistical analysis
The Mann–Whitney U test and the Kruskal-Wallis test
were used to determine significant differences. A p-value
of less than 0.05 was considered significant. Statistical
analyses were performed using Prism software version 6
(GraphPad, San Diego, CA, USA).
Results
HFD-fed mice develop atrophic gastritis
To determine how diet-induced obesity affects the
pathogenesis of gastric mucosa, C57BL/6 mice were fed
either HFD (60 % calories from fat) or CD (10 % calories
from fat) and the histological changes of the gastric mu-
cosa were examined in a time-dependent manner. Com-
pared to the CD-fed mice, the HFD-fed mice exhibited
rapid weight gain at a rate of > 2 g per week during the
first 12 weeks. Thereafter, a moderate increase of 1 g per
week was observed from 12 to 20 weeks (Fig. 1a). The car-
dial mucosa showed hyperplasia at 1 week, prior to any
significant difference in body weight gain between the
CD- and HFD-fed groups (1.5 ± 0.29 in CD vs. 1.8 ± 0.4 in
HFD, p > 0.05) (Fig. 1a and 1b). At 3 weeks, a reduced par-
ietal cell number and morphological alterations of the
foveola in the stomach were observed, followed by glandu-
lar metaplasia and a complete loss of zymogenic and par-
ietal cells at 12 weeks after the initiation of HFD feeding
(Fig. 1b). Although the hyperplastic change of the gastric
foveolar epithelium was seen at 1 week in the HFD-fed
mice, few CD45+ infiltrated cells were present in HFD-fed
mice (Fig. 1b and 1d). However, after 3 weeks of feeding, a
substantial amount of infiltrated cells were seen to have
invaded the interglandular and basal spaces in accordance
with the development of hyperplasia (Fig. 1b and 1d). In
the antrum, slight mucosal hyperplasia was observed in
HFD-fed mice at 1 week after diet initiation. Both the car-
dia and antrum displayed a replacement of normal glan-
dular cells such as parietal and G cells with atypical and
irregular cells after 3 weeks of HFD feeding (Fig. 1b). Fur-
thermore, mildly dysplastic epithelia, with cells showing
enlarged nuclei, nuclear pseudostratification, and distinct
nucleoli, became apparent in the hyperplastic lesions of
HFD-fed mice at 12 weeks after feeding (Fig. 1c). A high
frequency of Ki67-positive proliferating cells was observed
in the hyperplastic and dysplastic stomach lesions of the
HFD-fed mice, whereas these cells presented a defined
proliferating zone in the CD-fed mice (Fig. 1e). These al-
terations rapidly progressed by 8 weeks of feeding (Fig. 2c).
At 20 weeks of feeding, the folds of the glossy gastric mu-
cosa were flat with a pale appearance, and polyp-like
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Fig. 1 Pathological changes of gastric mucosa owing to HFD-feeding. a Alteration of gains in body weights of C57BL/6 J mice fed CD (n = 10) or
HFD (n = 10) during 20 weeks. b Representative H&E-sections of the gastric cardia and antrum from mice fed CD or HFD for 1, 3, and 12 weeks.
c Magnified image of the gastric antrum in mice fed CD and HFD in Fig. 1b at 12 weeks after feeding (magnification, ×400). The cell nucleolus,
nuclear hypertrophy, dyspolarity, and pseudostratification were observed. d CD45 staining of the gastric mucosa of 1 and 3 week HFD-fed mice.
e Ki67-staining in the gastric mucosa of mice fed CD or HFD for 3 weeks. 5–10 mice were used in each analysis, and representative data
are shown
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lesions were observed in the cardia and fundic regions of
HFD-fed mice (arrows in Fig. 2a). At this point, the cell
infiltration was complete, and the normal gastric glands
were replaced by intestinal crypt-like structures at the car-
dial basal mucosa of HFD-fed mice (Fig. 2b). These results
indicate that HFD-feeding alters gastric epithelial integrity
even at the early phase of feeding and suggest that the oc-
currence of mucosal hyperplasia in the stomach was initi-
ated by inflammation-independent events.
Upregulation of intestinal markers in the gastric mucosa
We further examined whether the gastric mucosa in
HFD-fed mice exhibited features of intestinal mucosa.
We observed that the frequency of Alcian blue-stained
goblet cells, which are intestinal mucus cells, increased
as they spread across the gastric mucosa in HFD-fed
mice (Fig. 3a). Muc2, an intestinal type of mucin, was
ectopically expressed in the gastric mucosa only of
HFD-fed mice (Fig. 3a), indicating that gastric mucin
was converted to the intestinal type as has been observed
in most human gastric carcinomas [24]. The results of
gene expression analysis were consistent with the immu-
nohistological findings. The mRNA expression of Muc2
and Tff3 (a peptide co-expressed with Muc2) increased,
whereas that of the gastric-type mucins, Muc1, Muc5ac,
and Muc6, remained unaltered or decreased in the
Fig. 2 Development of gastric mucosal atrophy in diet-induced obese mice. a The gastric lumen was opened along the outer curvature of mice
fed CD or HFD for 20 weeks. Arrows indicate the polyp-like lesions in the stomach of HFD-fed mice. b Representative H&E-sections of the gastric
cardia and antrum from mice fed CD or HFD for 20 weeks. c The histological scores from the stomachs of mice fed CD or HFD (<3 weeks, 4–8
weeks, 8–20 weeks of feeding; 10 mice per group) were graded according to the diagnostic criteria described in the Methods. Results were ana-
lyzed by the Kruskal-Wallis test, followed by a Dunn’s multiple comparison test. * p < 0.05, ** p < 0.01, NS; not significant
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Fig. 3 Alteration of intestinal characteristics in the gastric mucosa of HFD-fed mice. Gastric sections stained for PAS-Alcian blue, Muc2, PLA2, and
H+K+ ATPase (a), and Cdx2 (d) in mice fed CD or HFD for 20 weeks. Gene expression of mucins (b), and Cdx2 and Sox2 (e) in the gastric mucosa
of mice fed CD or HFD at 1 to 12 weeks after feeding. We utilized 5–10 mice in each analysis, and representative data are shown. c The gastric
pH in the gastric lumen was measured according to the description provided in the Methods. Values represent the means ± SD of 5 mice. The
results were analyzed by the Kruskal-Wallis test. * p < 0.05
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stomachs of HFD-fed mice (Fig. 3b). The cardia of HFD-
fed mice also showed ectopic expression of phospholipase
A2 (PLA2), an intestinal Paneth cell marker (Fig. 3a). In
contrast, the expression of H+K+-ATPase, a marker of par-
ietal cells that secrete gastric acid, decreased with a con-
current elevation of gastric pH in the HFD-fed mice
(Fig. 3a and 3c). In addition, the deregulation of transcrip-
tion factor expression transposes into a metaplastic
phenotype. Accordingly, the mRNA expression of Cdx2,
an intestinal master transcription factor that is a marker
of intestinal metaplasia, was higher in HFD-fed mice at
1 week (Fig. 3e). Furthermore, Cdx2 mRNA expression
was increased in the gastric mucosa of HFD-fed mice at
12 weeks in contrast to that observed in CD-fed mice, in
which it was constant (Fig. 3d and 3e). Consistent with
the ectopic Cdx2 mRNA expression, the mRNA of Sox2, a
transcription factor for stomach organogenesis [25],
tended to be downregulated, indicating the development
of intestinal metaplasia in the gastric mucosa in HFD-fed
mice (Fig. 3e). Taken together, these results imply that
HFD-feeding accelerates intestinal metaplasia.
HFD feeding activates early leptin receptor signaling
during gastric intestinal metaplasia
Because of the early morphological alterations observed in
the gastric mucosa, we examined the gene expression of
stomach-specific hormones, peptides, and enzymes 1 week
after HFD feeding. Leptin mRNA expression in particular
was significantly higher in the stomach of HFD-fed mice;
in contrast, ghrelin expression was lower in HFD-fed mice
(Fig. 4a). The expression of other genes such as Atp4a,
Atp4b, Pga, and Pgc, which encode to H+K+-ATPase, pep-
sinogen A, and pepsinogen C, respectively, did not show
significant differences between CD- and HFD-fed mice, al-
though the expression of Atp4a and Atp4b tended to de-
crease (Fig. 4a). Normally, leptin is expressed in chief and
parietal cells [26, 27]; however, HFD-fed mice exhibited
strong leptin expression in the hyperplastic gastric epithe-
lia (Fig. 4b and 4c). Even though the serum leptin concen-
tration was similar between CD- and HFD-fed mice at
1 week after feeding (Fig. 4d), the leptin expression in the
hyperplastic region of the stomach was consistent with
the structural changes observed on H&E stained sections
at 1 week (Fig. 1b). The leptin expression continued to in-
crease to 12 weeks post HFD feeding, after which the ex-
pression approximately recovered to the level observed in
CD-fed mice at 20 weeks (Fig. 4b and 4c). Concomitant
with the high leptin expression at 1 week, phosphorylation
of ObRb, STAT3, Akt, and ERK, which are molecules as-
sociated with leptin receptor signaling, was detected in
the gastric mucosa of HFD-fed WT mice (Fig. 5a). These
molecules remained activated at 4 weeks after feeding. In
contrast, leptin-deficient ob/ob and ObR mutated db/db
mice did not show phosphorylated ObRb, and only
exhibited slightly activated STAT3, Akt, and ERK. In sup-
port of the validity of these findings, the isotype-control
Ab did not react specifically and no expression of p-ObRb
was detected in db/db mice (Fig. 5b and 5c).
Chronic inflammation can trigger atrophic gastritis.
IL-6 and IL-11, which are predominantly expressed in
the stomach, modulate inflammatory responses during
neoplastic progression [28, 29]. In particular, IL-11 ex-
pression increases in atrophic gastritis and in intestinal
metaplasia of the fundic mucosa [30]. To identify poten-
tial initiators of intestinal metaplasia, we examined the
expression of leptin, IL-6, and IL-11 in the gastric mu-
cosa. Whereas leptin was expressed at 1 week after feed-
ing, Il6 and Il11 mRNA levels did not increase in the
gastric cardia of HFD-fed mice until 3 weeks after diet
initiation (Fig. 6a). At 12 weeks, IL-11 expression ac-
companied an increased number of CD45+ infiltrated
cells (Fig. 6a and 6b). These findings suggest that HFD-
induced leptin expression and downstream activation
precedes the induction of inflammatory cytokines during
intestinal metaplasia.
Lack of leptin signaling suppresses gastric intestinal
metaplasia
HFD feeding activated leptin signaling, leading to intes-
tinal metaplasia in WT mice. Conversely, the absence of
leptin signaling should therefore suppress HFD-induced
gastric pathology. To investigate the role of leptin signal-
ing in the development of intestinal metaplasia, we exam-
ined gastric mucosal changes in leptin-deficient ob/ob
mice and leptin receptor-mutated db/db mice. The ob/ob
and db/db mice showed a higher body weight than did
WT mice; however, no significant difference in body
weights was observed between CD- and HFD-fed mice at
1 week after feeding (Additional file 3: Figure S1a). The
ob/ob and db/db mice fed the CD for 1 week exhibited
hyperinsulinemia, whereas only HFD-fed ob/ob mice
showed increased insulin levels. HFD-fed db/db mice
showed insulin levels similar to those of CD-fed db/db
mice, because of their insulin resistance (Additional file 3:
Figure S1b). The db/db mice also exhibited hyperleptine-
mia and hypergluconemia. However, the non-esterified
fatty acid (NEFA) concentration did not vary among
WT, ob/ob, and db/db mice fed with either CD or HFD
(Additional file 3: Figure S1b). Histopathological analysis
revealed that compared to the WT mice, ob/ob and db/db
mice that were obese and insulin- or leptin- resistant
showed few morphological changes such as hyperplasia of
the gastric cardial mucosa at 1 week after initiation of
HFD feeding (Fig. 7a). Mucosal height analysis was con-
sistent with the histological findings (Fig. 7c). Further-
more, immunohistochemical analysis revealed increased
colocalization of Cdx2 and leptin in the gastric mucosa of
WT mice fed the HFD for 1 week (Fig. 8a), whereas db/db
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Fig. 4 (See legend on next page.)
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mice did not show Cdx2 expression in leptin-positive
cells. In contrast, ob/ob mice showed little Cdx2 and no
leptin expression. Similarly, co-localization of phosphory-
lated ObRb and Cdx2 was detected in HFD-fed WT mice,
but not in HFD-fed ob/ob or db/db mice, which showed
only some phosphorylation of ObRb or Cdx2, respect-
ively. CD-fed ob/ob and db/db mice showed a drastic
increase in body weight but only slight hyperplasia in
the gastric mucosa compared to WT mice at 3 weeks
(Fig. 7b and 7c). Despite having higher body weights,
ob/ob and db/db mice fed the HFD for 3 weeks exhib-
ited less hyperplasia than did WT mice fed the HFD for
20 weeks. After 20 weeks of HFD feeding, the WT mice
presented an irregular and fused structure in the cardia
(Fig. 7b). HFD feeding did not increase the expression of
Cdx2 and Muc2 in the gastric mucosa of ob/ob and db/db
mice (Fig. 8b). These results suggest that leptin signaling
in the stomach is an important factor that leads to meta-
plastic pathology in obesity-related gastritis.
Discussion
This study presents the first evidence supporting the the-
ory that HFD-induced enhanced leptin receptor signaling
in the gastric mucosa causes atrophic gastritis in a murine
model. We found that HFD feeding triggers leptin produc-
tion and the activation of leptin-ObR signaling in the gas-
tric mucosa, promoting atrophic gastritis and intestinal
metaplasia. Given the higher frequency of gastritis in
obese patients [31, 32], our results substantiate the role of
leptin receptor signaling in obesity-induced atrophic gas-
tritis. H. pylori infection is considered a major cause of
chronic gastritis and GC [33, 34]; however, very few H.
pylori-infected patients develop GC [35]. Furthermore,
the frequency of gastritis is significantly higher in mor-
bidly obese patients, whereas the prevalence of H. pylori
infection is similar in obese and non-obese individuals [2].
Thus, obesity is an important factor accounting for the
prevalence of histologic gastritis and the transformation of
gastric mucosal cells in addition to H. pylori infection.
In addition to adipose tissue, the placenta [36] and
mammary glands [37, 38] also produce leptin, which
supports trophoblast cell proliferation to regulate fetal
growth and development [39, 40] and the development
of the mammary gland, respectively. In those tissues,
leptin is produced in both normal and malignant cells,
and its overexpression has been demonstrated in neo-
plastic cells [36, 41]. Elevated expression of leptin and
ObRb is associated with faster tumor recurrence and
mortality in human grade-III invasive breast tumors
[42, 43]. Tumor cells derived from MMTV-Wnt1 mice,
a widely used model of mammary tumors, show de-
creased growth in ob/ob mice compared with cells from
diet-induced obese mice that have functional leptin sig-
naling [44]. Our data show that ob/ob and db/db mice
show no activation of the ObR, a marked decrease in
the activation of STAT3, Akt, and ERK (Fig. 5a), and ex-
hibit less progression of gastric hyperplasia even though
these mice are more obese than HFD-fed WT mice
(Fig. 7). Furthermore, ob/ob and db/db mice do not
spontaneously develop gastric tumors although these
mice exhibit extraordinary obesity. Thus, the results of
our study together with those of the previous reports
imply that leptin signaling is critically involved in the
control of epithelium development in a variety of tis-
sues. Although the significance of leptin expression and
its signaling in the stomach remains uncertain, consid-
ering the constitutive expression of leptin and ObRb in
the stomach [45, 46], leptin might be necessary for the
maintenance of gastric mucosal homeostasis.
Leptin is considered to represent a key player in
obesity-associated gastrointestinal malignancies because
of its roles in angiogenesis, apoptosis, cell proliferation,
and cell migration, which support the milieu of tumor
development and progression [17]. Recently, leptin was
shown to contribute to mucin production and the for-
mation of gastrointestinal neoplasms by modulating
mTOR-, STAT3-, and ERK-dependent pathways [47] in
addition to PKC-, PI3K-, and MAPK-dependent path-
ways [48, 49]. The mechanisms underlying the induction
of gastric atrophy are not defined; however, transcription
factors responsible for cell differentiation have been re-
ported to be potently involved in gastric tumorigenesis.
Transcription factors such as Cdx2 and Sox2 are critical
for cell self-renewal and the maintenance of cells in ap-
propriate proportions [50]. Sox2 is a primary regulator
of gastric differentiation that maintains gastric mucosal
features and regulates the expression of gastric mucus
genes, such as Muc5ac [51], and it is downregulated dur-
ing the development of gastric adenocarcinoma [52, 53].
In contrast, Cdx2 is essential for intestinal epithelium dif-
ferentiation to regulate the expression of Muc2 [54, 55]
and Tff3 [56], and it is upregulated during the progression
of gastric tumors [57]. Recently, the binding of phosphory-
lated STAT3 to the Cdx2 promoter region was shown to
(See figure on previous page.)
Fig. 4 Enhancement of gastric leptin expression in the early period of HFD feeding. a Gene expression of gastric-specific molecules at 1 week
after CD and HFD feeding. b Gastric sections stained for leptin in mice fed CD or HFD for 1, 12, and 20 weeks. c Quantification of leptin expression in
(b). The data are presented as the relative expression at each time-point to the expression level in the antrum of CD-fed mice after 1 week. d Serum
leptin concentration in mice fed CD and HFD for 1 week. The values represent the means ± SD of 5 mice. The results were analyzed by the
Mann–Whitney U test. * p < 0.05, ** p < 0.01
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upregulate Cdx2 but downregulate Sox2 in two gastric cell
lines, MKN45 and NUGC4 [58]. In this study, we showed
that HFD feeding induces Cdx2 and Muc2 expression as-
sociated with increased leptin levels (Figs. 3 and 8), sug-
gesting the possibility that leptin acts to suppress cellular
protection against gastric mucosal malignancies in the
early stage of atrophic gastritis.
Atrophic gastritis is characterized by an alteration of
the differentiation of gastric mucosal cells such as the
loss of parietal and chief cells and replacement of the
Fig. 5 Upregulation of leptin receptor signaling in the gastric mucosa of HFD-fed WT mice. a Western blot analysis of the phosphorylation of
ObRb, STAT3, Akt and ERK1/2 in the gastric mucosa of WT, ob/ob and db/db mice fed CD and HFD for 1 and 4 weeks. A total of 3 mice were used
in each diet group per one experiment. Each experiment was repeated twice and representative data are shown. b Immunohistochemistry and
(c) western blot analysis of phosphorylation of ObR in the gastric mucosa of db/db mice and WT mice fed CD or HFD for 3 weeks. We utilized 3
mice in each analysis, and representative data are shown. Arrows indicate phosphorylated ObR-positive cells
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destroyed glandular structure with a diffuse intestinal mu-
cous metaplasia [59]. Variations in the pathology of atro-
phic gastritis have been reported to some degree in
genetically engineered mice such as Atp4a−/− and gastrin−/−
mice, which are used as models of parietal and glandular
cell loss. However, Atp4a−/− mice exhibit the same expres-
sion levels of Muc2 and Tff3 in the gastric mucosa as con-
trol Atp4a+/+ mice, indicating incomplete intestinalization
of the gastric mucosa in these mice [60]. Gastrin is secreted
from G-cells to stimulate acid secretion and cell prolifera-
tion of the fundic mucosa [61]. Gastrin−/− mice develop an-
tral gastric neoplasia with increased levels of Muc2 and
villin (an intestinal-specific actin bundling protein) in the
gastric mucosa in the presence of gastric inflammation but
not in the fundus [62, 63]. As proinflammatory cytokines
involved in atrophic gastritis, IL-6 and IL-11 cause an
inflammatory response in the stomach and play important
roles in angiogenesis and cell proliferation during the pro-
gression of neoplasia [28, 29]; thus, they are used as bio-
markers of aggressive tumors [64]. In particular, IL-11,
which is mainly expressed in the fundic mucosa, might play
a pivotal role in atrophic gastritis and the progression of
GC [30, 65]. Chronic treatment of WT mice with recom-
binant IL-11 induces atrophy in the gastric fundus, includ-
ing the cardia, with reduced parietal cells and highly
phosphorylated STAT3, but no features of intestinalization
of the gastric mucosa such as the appearance of goblet cells,
Muc2, and Cdx2. These reports raise the question of which
molecules are directly involved in the atrophy of the gastric
mucosa associated with metaplasia. In our study, the in-
crease of gastric leptin expression is observed during the
early period after the initiation of HFD feeding and its
Fig. 6 Delayed induction of proinflammatory cytokines in the gastric mucosa after HFD-feeding. a Gene expression of leptin, Il6, and Il11 in the
gastric mucosa of CD- and HFD-fed mice after 1, 3, and 12 weeks. The values represent the means ± SD of 4 mice. The results were analyzed by
the Kruskal-Wallis test. * p < 0.05, p < 0.01. b Immunohistological staining of the stomach sections of the CD and HFD-fed mice with Abs against
IL-11 and CD45
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subsequent reduction is consistent with the loss of normal
parietal and chief cells, which constitutively produce leptin
and ObR [26, 27], in the gastric mucosa of HFD-fed mice
in accordance with the development of intestinal metaplasia
after 20 weeks of HFD feeding (Figs. 1, 2 and 3). Our results
might therefore directly indicate the involvement of leptin
receptor signaling in the initiation of obese-associated gas-
tric atrophy.
The involvement of gastric leptin in diet-induced
obesity-associated gastric atrophy has not previously
been investigated, although the elevation of serum leptin
contributes to tumorigenesis in the stomach of obese
mice infected with H. felis [66]. In the current study, we
showed rapid (1 week) mucosal morphological changes in
the gastric cardia (Fig. 1b) in accordance with high expres-
sion of gastric leptin at this time (Fig. 4d). Furthermore,
prior to the production of IL-11, leptin expression in the
cardial gastric mucosa increases, concurrent with the hy-
perplastic lesions observed in the early period after HFD
feeding (Fig. 4b and 6). The localization of leptin-producing
cells within cardial mucosal lesions occurs during the early
stage of atrophy in HFD-fed mice. Furthermore, the in-
creased leptin levels and activation of ObRb resulted in in-
creased levels of phosphorylated STAT3 in the HFD-fed
mice (Fig. 5a). Notably, because ob/ob and db/db mice do
not transduce leptin receptor signaling and do not show
Fig. 7 Suppressed alteration of gastric morphology in HFD-fed mice devoid of leptin signaling. Representative H&E-sections of the gastric mucosa
from WT, ob/ob and db/db mice fed CD or HFD for 1 (a) and 3 weeks (b). Each value in the images indicates the body weight of the mouse from
which the gastric mucosa was obtained and stained with H&E-stain. c Measurement of mucosal height in the gastric fundus of WT, ob/ob and db/db
mice at 1 and 3 weeks and of WT mice at 20 weeks after feeding. The values represent the means ± SD of 4 mice. The results were analyzed by the
Kruskal-Wallis test. * p < 0.05, ** p < 0.01
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morphological alterations such as loss of glandular
structure (Fig. 5a and 7), the elevation of gastric leptin
by HFD feeding might initiate a reduction of glandular
structure by diffuse metaplasia, i.e., a loss of parietal and
chief cells. Since most parietal and chief cells residing in
the fundic mucosa of the stomach express leptin and
ObRb [26, 45, 46], it would be interesting to investigate
how these cells respond to food-based stimulants such
as fatty acids in the HFD.
In summary, we demonstrated the development of
atrophic gastritis using a murine model of diet-induced
obesity with an enhanced leptin-ObRb signaling path-
way. The expression and unique localization of the
leptin-ObR signaling pathway predominantly indicates a
role in the early phase of human GC. The significance of
this study lies in the potential and invaluable use of lep-
tin and ObR as biomarkers or as new therapeutic targets
for the diagnosis and treatment of atrophic gastritis.
Conclusion
In this study, we show that diet-induced obese WT mice
exhibit overexpression of leptin and activation of leptin
receptor signaling in the gastric mucosa, leading to atro-
phic gastritis with intestinal metaplasia of the gastric
mucosa. These pathological features are less severe in
ob/ob and db/db mice, which lack leptin receptor signal-
ing, than in the WT mice. Therefore, leptin receptor sig-
naling in the stomach is a critical checkpoint for the
onset of gastric neoplasia, and preventive therapeutics
targeting gastric leptin receptor signaling might be de-
veloped against GC.
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